Author

Michael L. Cheng

University of California, San FranciscoORCID 0000-0002-7409-288XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Research Focus:perturbation response prediction· 1

Frequent Co-Authors

Aaron C. LoganiD· 1 shared Andrew Koh· 1 shared Bogdan PopescuiD· 1 shared Carolina Morales· 1 shared Catherine Choy SmithiD· 1 shared Cheryl A.C. PeretziD· 1 shared Elaine TraniD· 1 shared Elliot StieglitziD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Aaron C. LoganORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Multi-selective RAS(ON) Inhibition Targets Oncogenic RAS Mutations and Overcomes RAS/MAPK-Mediated Resistance to FLT3 and BCL2 Inhibitors in Acute Myeloid Leukemia

Bogdan Popescu, Matthew F. Jones, Madison Piao, Elaine Tran, Andrew Koh, Isabelle Lomeli, Cheryl A.C. Peretz, Natália Faraj Murad, Sydney Abelson, Carolina Morales, José M. Rivera, Yana Pikman, Michael L. Cheng, Aaron C. Logan, Elliot Stieglitz, Catherine Choy Smith

This study evaluates RMC-7977, a RAS(ON) inhibitor, showing efficacy against RAS-driven resistance in AML and potential for combination therapies.

bioRxiv · Jun 10, 2025 · PreprintCancer Biology